A Phase 1 Open-Label Study of the Safety Tolerability and Efficacy of KPT-9274 A Dual Inhibitor of PAK4 and NAMPT in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma (PANAMA)

Brief description of study

if you are newly diagnosed with non-Hodgkin's lymphoma or advanced solid malignancies, you may qualify to participate in a clinical trial.  The main goal of this phase I study is to evaluate the safety, tolerability, and efficacy of an investigational drug, oral KPT-9274 for the treatment of your diseases.


Clinical Study Identifier: s16-00464
ClinicalTrials.gov Identifier: NCT02702492
Principal Investigator: Daniel C Cho
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.